logo
EU Threatens Donald Trump With $24.5 Billion Tariff List

EU Threatens Donald Trump With $24.5 Billion Tariff List

Miami Herald14-07-2025
The European Union has readied a set of retaliatory tariffs totaling 21 billion euros ($24.5 billion) on U.S. goods, officials warned on Monday.
Italy's Foreign Minister and Deputy Prime Minister Antonio Tajani stated in an interview with Il Messaggero that the EU remains open to negotiations and is intent on avoiding a trade war with the U.S, but will respond with these substantial tariffs if a deal with the U.S. fails to materialize.
The threat comes after President Donald Trumpannounced a new 30 percent tariff on Mexican and E.U. imports, set to take effect on August 1.
Newsweek has reached out to the White House for comment outside of regular hours.
The reescalation of trans-Atlantic trade tensions follows weeks of stalled negotiations and the pair trading threats of even higher duties. While European leaders have confirmed they will delay countermeasures until early August to allow for open and amicable dialogue, these and the tariffs that motivated them threaten the nearly $1 trillion in bilateral trade between the EU and U.S.
The higher tariffs and potential retaliation also pose a risk to global supply chains, particularly for industries such as automobiles, pharmaceuticals and agriculture, and could lead to higher consumer prices on both sides of the Atlantic.
On Saturday, President Trump announced his intention to impose 30 percent tariffs on all imports from the EU and Mexico. For the former, Trump cited persistent trade deficits—the E.U. posted a trade surplus of $235.6 billion with the U.S. last year—and said that this posed "a major threat to our Economy and, indeed, our National Security."
European leaders expressed frustration with the announcement, with Bernd Lange, chair of the European Parliament's committee on international trade calling it "a slap in the face." Officials also expressed their desire to work toward an agreement with the U.S, but stressed that firm countermeasures would be necessary should such negotiations fail.
"We remain ready to continue working toward an agreement by August 1," said European Commission President Ursula von der Leyen. "At the same time, we will take all necessary steps to safeguard EU interests, including the adoption of proportionate countermeasures if required."
In pursuit of the former, von der Leyen announced that the EU would suspend previous retaliatory countermeasures against existing U.S. tariffs on steel and aluminum imports, which were set to come into effect on Tuesday.
Italy's foreign minister said that the best path forward for both the U.S. and EU is zero tariffs and "an open market between Canada, the United States, Mexico and Europe." He added that, in addition to the $24.5 billion duties prepared in response to the tariff threats, a second package of countermeasures "could be added."
However, in the letter sent to the EU, shared on Truth Social, Trump warned: "If for any reason you decide to raise your Tariffs and retaliate, then, whatever the number you choose to raise them by will be added onto the 30% that we charge."
To insulate the bloc's economies from Trump's tariffs, should these take effect, Tajani also called for the European Central Bank to pursue a quantitative easing, bond-buying program like the one undertaken during the COVID pandemic, though he acknowledged many European leaders are currently against this proposal.
Antonio Tajani, Italian Foreign Minister, told Il Messaggero on July 14, 2025: "A list of European duties worth 21 billion euros is ready, to which a second could be added. I am confident that there will be progress."
"The tariffs hurt everyone, starting with the United States," he added. "If the stock markets go down, Americans' pensions and savings are at risk. I repeat: our goal, in perspective, is zero duties. An open market between Canada, the United States, Mexico and Europe."
Ursula von der Leyen, European Commission President, in a statement released Saturday, said: "Imposing 30 percent tariffs on EU exports would disrupt essential trans-Atlantic supply chains, to the detriment of businesses, consumers and patients on both sides of the Atlantic."
French President Emmanuel Macron, via X, said: "[Trump's] announcement comes after weeks of intense engagement by the Commission in negotiations with the United States, on the basis of a solid offer made in good faith.
"With European unity, it is more than ever up to the Commission to assert the Union's determination to resolutely defend European interests. In particular, this implies speeding up the preparation of credible countermeasures, by mobilizing all the instruments at its disposal, including anti-coercion, if no agreement is reached by August 1st."
Macron added that negotiations will now "intensify," to secure "a mutually acceptable agreement by August 1st."
The pause placed on countermeasures by the E.U, and only two weeks until Trump's latest duties come into effect, both sides have a narrow window to negotiate a compromise and avoid a major escalation in the trade war.
Tajani told Il Messaggero that, rather than a fully fledged trade deal, the two sides could feasibly secure an in-principle agreement which would delay tariffs and countermeasures, and provide more time for the remaining details to be finalized.
The EU's trade ministers are set to meet in Brussels on Monday to formulate a cohesive response to the tariffs, the BBC reports.
Related Articles
The Inconvenient Americans | OpinionTrade Chief Issues Trump Tariff Warning: 'Almost Impossible'Map and List of Cities Hosting Anti-Trump Protests on July 17Donald Trump's Approval Rating Changes Amid Epstein Files Backlash
2025 NEWSWEEK DIGITAL LLC.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Shopify Stock Is Rising Today
Why Shopify Stock Is Rising Today

Yahoo

time16 minutes ago

  • Yahoo

Why Shopify Stock Is Rising Today

Key Points Investors may be responding to the fact that the E.U. said it won't increase tariffs on the U.S. just yet. But slowing job growth and uncertainty around tariffs could eventually weigh on the economy. Shopify investors should keep a close watch on the company's upcoming quarterly results. 10 stocks we like better than Shopify › Shares of the e-commerce platform company Shopify (NASDAQ: SHOP) were rebounding today after stumbling on Friday after a weaker-than-expected jobs report. Investors regained some of their optimism for the company today, as the European Union says it's delaying some retaliatory tariffs on the U.S. for six months. Shopify investors are closely watching for any positive economic news as they prepare for the company's Q2 earnings report due out on Wednesday. Shopify stock was up by more than 5% this morning and had gained 4.8% as of 11:29 a.m. ET. Some positive news ahead of Shopify's upcoming earnings report Profit growth has been slowing for Shopify, and investors will get more details on which direction it's currently headed when the company reports second-quarter results on Wednesday. In the meantime, investors were responding positively to the E.U.'s announcement that it will hold off on any retaliatory tariffs against the U.S., as it tries to strike a trade deal. Investors were spooked on Friday by a weak jobs report for June and significantly revised jobs numbers for May, which caused a sell-off among many stocks on Friday. So any news that the U.S. isn't entering a new stage of a trade war with the E.U. caused investors to respond positively. Shopify's growth is dependent on how well companies are growing in the U.S. and how many new businesses are started. So any slowdown in the economy will weigh down the company's sales and earnings. The latest job data wasn't a good sign, but with today's gains, it appears investors aren't yet sold on the idea that the U.S. economy is slowing down. Shopify investors will know more very soon Wednesday's Q2 report will prove whether investors' optimism is misplaced or not. It's certainly not time to panic about the economy, but there are significant uncertainties right now as hiring slows down and the dust settles on new tariffs. It could take months for both to work their way through the economy, which means the next few quarters will be especially important to watch for Shopify investors. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Is Rising Today was originally published by The Motley Fool

Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033
Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033

Yahoo

time16 minutes ago

  • Yahoo

Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033

Innovation now defines the organ care products market. Advanced perfusion and portable systems are actively expanding the donor organ pool, tackling immense waiting lists driven by chronic diseases and dramatically improving success rates for vital transplants. Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global organ care products market was valued at US$ 199.20 million in 2024 and is expected to reach US$ 812.12 million by 2033, growing at a CAGR of 16.90% during the forecast period 2025–2033. The current scenario in the organ care products market is one of explosive growth, fueled by the twin engines of unprecedented global demand and transformative technology. In 2024, the U.S. performed a record 48,149 transplants, yet this barely meets the need, as regions like Eurotransplant still have over 13,570 patients on waiting lists. This profound supply-demand imbalance is accelerating a fundamental shift away from traditional static cold storage towards advanced perfusion and assessment systems. These technologies are directly addressing the critical issue of organ non-utilization, aiming to convert a portion of the thousands of organs discarded annually into life-saving opportunities, thereby changing the entire calculus of transplantation. Request Sample Pages: This evolution is being aggressively capitalized upon by key industry players through strategic expansion and is buoyed by substantial investment. Recent developments, such as Paragonix's EU MDR certification for five devices in March 2025 and its rapid U.S. commercial expansion, highlight a fierce race to capture market share. The market's momentum is further underwritten by significant capital influx, from government initiatives like the $67 million allocated for U.S. transplant system modernization in FY2025 to targeted research funding from organizations like Enduring Hearts. The current scenario is therefore not just about growth, but about a well-funded, strategic push to commercialize innovation on a global scale. Key Findings in Organ Care Products Market Market Forecast (2033) US$ 812.12 million CAGR 16.90% Largest Region (2024) North America (56%) By Organ Type Kidney (28%) By Product Type Trolly (53%) Top Drivers Rising global incidence of chronic diseases fuels organ transplant demand. Technological advancements in organ preservation systems improve transplant success rates. Favorable reimbursement policies encourage organ transplant procedures, boosting market growth. Top Trends Emergence of normothermic machine perfusion for real-time organ function assessment. Development of smaller, portable organ preservation devices for easier transport. Focus on developing organ-specific preservation solutions for better patient outcomes. Top Challenges Complex ethical and logistical hurdles in organ procurement and allocation. Unprecedented Transplant Volumes Are Fueling Robust Market Expansion and Demand The foundational driver for the organ care products market is the sheer volume of surgical procedures, which continued its upward trajectory through 2024. In the United States alone, a record of over 48,000 organ transplants were performed. This milestone was confirmed with a final tally of 48,149 procedures for the year, marking the first time the nation has exceeded this figure. This represents an impressive average of 132 organ transplants performed each day in the U.S. throughout 2024. Critically, 2024 marked the 14th consecutive year of growth in the number of organs recovered for transplants in the U.S., signaling a sustained and reliable increase in the core activity that underpins the market. This trend is not isolated; globally, organ transplantation activities saw a notable increase in 2023, which has set a strong precedent for continued growth in 2024 and beyond. In Europe, the eight Eurotransplant countries allocated 7,150 organs from deceased donors in 2024, while in China, a remarkable 24,684 transplant surgeries were performed during the same year, showcasing the truly global nature of this expansion. The Critical Role of Organ Procurement in Shaping Market Dynamics The availability and procurement of donor organs represent the starting point for the entire transplantation value chain, directly influencing the organ care products market. In the United States, 55 dedicated organ procurement organizations (OPOs) were operational as of October 2024, forming the backbone of the recovery network. In 2024, these U.S. OPOs successfully recovered over 45,000 organs for transplant procedures. This was made possible by the 16,989 Americans who became deceased organ donors, a testament to growing awareness and consent. These efforts were supplemented by more than 7,000 living donors in the U.S. in 2024. An interesting demographic trend shows that nearly 8,200 of the deceased donors in the U.S. in 2024 were aged 55 and older, highlighting the expanding criteria for donation. In the United Kingdom, from April 2023 to March 2024, there were 1,510 deceased organ donors and 938 living organ donors. Across the Eurotransplant region, organs were sourced from 2,181 deceased donors in 2024. Meanwhile, China recorded 6,744 cases of organ donations in 2024, with the number of registered organ donors soaring to over 7.05 million by early 2025, indicating massive future potential. Organ-Specific Procedural Growth Creates Niche Opportunities Within the Market A deeper analysis of procedural data reveals that growth is not uniform across all organ types, creating distinct and lucrative opportunities within the organ care products market for specialized preservation technologies. In the United States during 2024, cardiac procedures were significant, with 4,572 heart transplants performed. Thoracic procedures were also prominent, as the number of lung transplants reached 3,340. Abdominal transplants, which constitute the largest segment, saw a total of 11,458 liver transplants and an impressive 27,759 kidney transplants performed in the U.S. in 2024. This high volume in renal transplantation underscores the demand for reliable kidney preservation solutions. Furthermore, specialized procedures are gaining traction; in the UK, for instance, 65 Donation after Circulatory Death (DCD) heart transplants took place in the 2023/24 period, a complex procedure that relies heavily on advanced preservation technology to ensure viability. Diverse Regional Landscapes Present Unique Challenges and Growth Avenues The global organ care products market is characterized by significant regional variations in infrastructure, regulatory frameworks, and donation patterns. China's market, for example, is notable for its scale; as of early 2025, there have been more than 58,000 cumulative organ donations to date. The country has also recorded over 63,000 body donations and 110,000 corneal donations as of 2025, pointing to a well-established and growing donation culture. In the UK, the data from 2023-2024 provides a detailed look at the procurement funnel, with 772 donors after brain death (DBD) and 738 donors after circulatory death (DCD). That year, there were 6,794 potential deceased organ donors identified in the UK, of whom 6,421 were formally referred as potential donors. From that pool, donation requests were made to families in 3,107 cases, ultimately resulting in 1,880 consented donors, illustrating the multi-step process where advanced care technology can play a role in boosting confidence and consent. Groundbreaking Product Innovation and Regulatory Wins Propel Market Leaders Forward Innovation is the lifeblood of the organ care products market, with regulatory approvals serving as key milestones that unlock new commercial opportunities. In October 2024, Paragonix Technologies achieved a major milestone with FDA 510(k) clearance for its KidneyVault portable renal perfusion system. This strategic clearance solidified Paragonix as the only company possessing U.S. regulatory clearances for advanced preservation devices for all five solid organs used in transplants. Earlier in the year, in June 2024, the company launched its PancreasPak, the world's first FDA-cleared preservation device for donor pancreases, with pre-orders beginning on June 27, 2024, and full commercial availability planned for September 1, 2024. In April 2024, Paragonix also announced the full U.S. commercial launch of its BAROguard Donor Lung Preservation System. During its limited market release, 5 of the top U.S. thoracic transplant centers had already deployed the BAROguard System. The momentum continued into 2025, when Paragonix received EU MDR approval for five of its organ preservation devices in March. These specific product approvals stood out in a year where the FDA approved a total of just 21 medical devices overall in 2024. Strong Financial Performance and Strategic Investments Signal a Healthy Marketplace The financial health and strategic initiatives of key industry players in the organ care products market provide compelling evidence of a vibrant and growing market. XVIVO Perfusion reported strong results for 2024, with net sales amounting to SEK 822.4 million for the full year. The fourth quarter of 2024 was particularly robust, with net sales reaching SEK 227.6 million. The company's profitability was also solid, with an operating income (EBIT) for Q4 2024 of SEK 15.5 million and an operating income before depreciation and amortization (EBITDA) of SEK 51.9 million. Strong operational execution led to a cash flow from operating activities of SEK 62.1 million in Q4 2024, and the company posted a net profit for the full year 2024 of SEK 172.2 million. On the utilization front, Paragonix preservation devices have been used in over 10,000 transplant cases globally as of March 2025, demonstrating deep market penetration. Specifically, the Paragonix SherpaPak and LUNGguard systems are utilized at over 150 transplant centers globally, including over 40 transplant centers in the EU, highlighting the company's expanding international footprint. Modernization Initiatives and Research Funding Pave the Way for Future Growth Substantial government and institutional investments in research and system modernization are creating a fertile ground for the future growth of the organ care products market. The U.S. Senate Appropriations Committee has included a significant $67 million in funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative for fiscal year 2025. This represents a $13 million increase over FY 2024 levels. The FY24 funding package had already included an additional $23 Million for the HRSA OPTN Modernization Initiative, bringing the total for that year to $52 Million. In 2024, the Mid-America Transplant Foundation's Clinical Innovation Fund began offering awards of up to $150,000 per year for three years to spur new research. The American Society of Transplantation (AST) is furthering this by offering a research grant of $75,000 for one year, with a term starting January 1, 2025. The International Society for Heart & Lung Transplantation is offering a grant of up to $75,000 for research into DCD heart transplantation, with recipients to be announced in January 2025, and a second grant of up to $37,500 for acellular Ex Vivo Lung Perfusion (EVLP) research. In 2024, the Scandiatransplant Research grant also supported two projects with 100,630 DKK and 260,000 DKK, respectively. Need a Customized Version? Request It Now: Addressing Organ Utilization and Waiting Lists Remains a Core Market Imperative The persistent challenges of organ non-utilization and extensive patient waiting lists serve as powerful catalysts for the organ care products market, driving the need for technologies that can preserve, assess, and improve marginal organs. In 2024, a concerning 9,275 recovered kidneys in the U.S. were ultimately not used for transplant, continuing a trend that highlights a critical gap between recovery and utilization. To combat this, OPOs have hosted eleven Transplant Growth Collaborations over the past year to share successful practices. Advanced perfusion is emerging as a key solution; a 2024 study of 803 transplantations, of which 174 received Normothermic Machine Perfusion (NMP), showed NMP was associated with a reduced need for early relaparotomy in liver transplants. Another 2024 study involving 118 NMP-treated livers matched with 236 preserved with static cold storage, and a cohort matching 37 NMP-DCD livers with 74 using static cold storage, are providing crucial data on efficacy. Global Organ Care Products Market Major Players: Bridge to Life Ltd. TransMedics Inc. Organ Recovery system XVIVO Preservation Solution Inc. Paragonix technologies and IGL OrganOx Limited Other Prominent Players Key Market Segmentation: By Organ Type Kidney Liver Heart Lungs Others By Product Type Trolly Portable By Region North America Europe Asia Pacific Middle East Africa South America Request a Personalized Report Walkthrough with Our Research Team: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cocoa Prices Pressured as Supply Concerns Ease
Cocoa Prices Pressured as Supply Concerns Ease

Yahoo

time16 minutes ago

  • Yahoo

Cocoa Prices Pressured as Supply Concerns Ease

September ICE NY cocoa (CCU25) today is -49 (-0.60%), and September ICE London cocoa #7 (CAU25) is down -111 (-2.02%). Cocoa prices are sliding today, with NY cocoa posting a 2-week low and London cocoa posting a 1-week low. Cocoa prices are under pressure on speculation that cocoa will be exempt from President Trump's tariffs, which would ease supply concerns. US Commerce Secretary Lutnick noted last week that goods not produced in the US could be exempted from tariffs. More News from Barchart Is the Corn Market Undervalued? Below-Average Rain in Brazil Supports Coffee Prices Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Last week, cocoa prices rallied to 1-month highs on concern that the slowdown in the pace of Ivory Coast cocoa exports could tighten global supplies. Today's government data showed that Ivory Coast farmers shipped 1.76 MMT of cocoa to ports this marketing year from October 1 to August 3, up +6% from last year but down from the much larger +35% increase seen in December. Concerns about dry weather in West Africa are also bullish for cocoa prices. According to the European Centre for Medium-Range Weather Forecasts, rainfall in the Ivory Coast and Ghana this season remains below the 30-year average, and combined with high temperatures, risks hurting cocoa pod development for the main crop harvest that starts in October. Concerns over tepid chocolate demand are bearish for cocoa prices. Last month, chocolate maker Lindt & Spruengli AG lowered its margin guidance for the year due to a larger-than-expected decline in first-half chocolate sales. Also, chocolate maker Barry Callebaut AG reduced its sales volume guidance earlier this month for a second time in three months, citing persistently high cocoa prices. The company projects a decline in full-year sales volume and reported a -9.5% drop in its sales volume for the March-May period, the largest quarterly decline in a decade. Cocoa prices sold off last month, with NY cocoa sinking to an 8.5-month nearest-futures low and London cocoa slumping to a 17-month nearest-futures low. Weakness in global cocoa demand has hammered prices. The European Cocoa Association reported on July 17 that Q2 European cocoa grindings fell by -7.2% y/y to 331,762 MT, a bigger decline than expectations of -5% y/y. Also, the Cocoa Association of Asia reported that Q2 Asian cocoa grindings fell -16.3% y/y to 176,644 MT, the smallest amount for a Q2 in 8 years. North American Q2 cocoa grindings fell -2.8% y/y to 101,865 MT, which was a smaller decline than the declines seen in Asia and Europe. In a bearish development, ICE-monitored cocoa inventories held in US ports reached a 10.5-month high of 2,368,141 bags on July 22. Higher cocoa production by Ghana is bearish for cocoa prices. On July 1, the Ghana Cocoa Board projected the 2025/26 Ghana cocoa crop would increase by +8.3% y/y to 650,000 from 600,000 MT in 2024/25. Ghana is the world's second-largest cocoa producer. Cocoa prices have support from quality concerns regarding the Ivory Coast's mid-crop cocoa, which is currently being harvested through September. Cocoa processors are complaining about the quality of the crop and have rejected truckloads of Ivory Coast cocoa beans. Processors reported that about 5% to 6% of the mid-crop cocoa in each truckload is of poor quality, compared with 1% during the main crop. According to Rabobank, the poor quality of the Ivory Coast's mid-crop is partly attributed to late-arriving rain in the region, which limited crop growth. The mid-crop is the smaller of the two annual cocoa harvests, which typically starts in April. The average estimate for this year's Ivory Coast mid-crop is 400,000 MT, down -9% from last year's 440,000 MT. Another supportive factor for cocoa is smaller cocoa production in Nigeria, the world's fifth-largest cocoa producer. Nigeria's Cocoa Association projects Nigeria's 2025/25 cocoa production will fall -11% y/y to 305,000 MT from a projected 344,000 MT for the 2024/25 crop year. On May 30, the International Cocoa Organization (ICCO) revised its 2023/24 global cocoa deficit to -494,000 MT from a February estimate of -441,000 MT, the largest deficit in over 60 years. ICCO said 2023/24 cocoa production fell by 13.1% y/y to 4.380 MMT. ICCO stated that the 2023/24 global cocoa stocks-to-grindings ratio declined to a 46-year low of 27.0%. Looking ahead to 2024/25, ICCO on February 28 forecasted a global cocoa surplus of 142,000 MT for 2024/25, the first surplus in four years. ICCO also projected that 2024/25 global cocoa production will rise +7.8% y/y to 4.84 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store